Evaluation of Adipokines and Metabolic Hormones in Coronary Artery Disease Patients: Association with Inflammatory and Oxidative Stress Biomarkers
Downloads
One of the common diseases affecting cardiovascular health is coronary artery disease, which is strongly associated with metabolic disorders, oxidative stress, and inflammation. This study aimed to evaluate the relationship between adipokines and metabolic hormones with markers of inflammation and oxidative stress. The study was conducted at Al-Sharqat General Hospital between January and March 2025, and included 60 patients with coronary artery disease and 30 individuals as a control group. The results showed a significant decrease in the levels of both adiponectin (ADPN) and ghrelin (GHRL) in the patient group compared to the healthy group. Conversely, the levels of leptin (LEP), C-reactive protein (CRP), and malondialdehyde (MDA) were elevated in the patient group compared to the control group. Correlation analysis revealed weak positive correlations between all variables, indicating an interconnected role of metabolic, inflammatory, and oxidative pathways in the development of the disease. The ROC curve analysis also showed strong diagnostic performance for all studied biomarkers, demonstrating their potential usefulness in diagnosing and monitoring the disease.
[1] P. Libby, “The changing landscape of atherosclerosis,” Nature, vol. 592, no. 7855, pp. 524–533, 2021.
[2] World Health Organization, “Cardiovascular diseases (CVDs),” 2023.
[3] V. Kumar, A. K. Abbas, and J. C. Aster, Robbins & Cotran Pathologic Basis of Disease, 10th ed. Elsevier, 2020.
[4] G. K. Hansson, “Inflammation, atherosclerosis, and coronary artery disease,” New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1695, 2017.
[5] N. R. Madamanchi, A. Vendrov, and M. S. Runge, “Oxidative stress and vascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 1, pp. 29–38, 2005.
[6] H. Yue et al., “Adiponectin protects against myocardial ischemia–reperfusion injury: A systematic review,” Lipids in Health and Disease, vol. 23, p. 51, 2024.
[7] K. Ma et al., “Endoplasmic reticulum stress: Bridging inflammation and obesity-associated adipose tissue,” Frontiers in Immunology, vol. 15, p. 1381227, 2024.
[8] C. Hong et al., “Autophagy–oxidative stress–inflammation axis in adipogenesis,” Frontiers in Endocrinology, vol. 15, p. 1404697, 2024.
[9] A. Klisic et al., “The role of oxidative stress in metabolic and inflammatory diseases,” Frontiers in Endocrinology, vol. 15, p. 1374584, 2024.
[10] Z. Noori et al., “Quercetin declines inflammation and augments adiponectin expression,” Molecular Biology Reports, vol. 51, no. 1, p. 445, 2024.
[11] S. Kafeel et al., “Adiponectin and its therapeutic potential in metabolic diseases,” Biomolecules, vol. 15, no. 6, p. 820, 2025.
[12] J. Peng, Q. Chen, and C. Wu, “The role of adiponectin in cardiovascular disease,” Cardiovascular Pathology, vol. 64, p. 107514, 2023.
[13] N. P. E. Kadoglou et al., “Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY,” Translational Research, vol. 155, no. 5, pp. 238–246, 2010.
[14] A. Ismaiel et al., “Leptin unveiled: A potential biomarker for acute coronary syndrome,” International Journal of Molecular Sciences, vol. 26, p. 3925, 2025.
[15] D. F. van Wijk et al., “C-reactive protein, fatal and nonfatal coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 12, pp. 2888–2894, 2013.
[16] H. N. Asfandiyar et al., “Estimation of serum malondialdehyde as a predictive biomarker for CAD severity,” Cureus, vol. 16, no. 9, p. e69756, 2024.
[17] Y. Zhou et al., “Decreased adiponectin and increased inflammation in epicardial adipose tissue,” Cardiovascular Diabetology, vol. 10, p. 2, 2011.
[18] J. Luo et al., “Adipokines in atherosclerosis: unraveling complex roles,” Frontiers in Cardiovascular Medicine, vol. 10, p. 1235953, 2023.
[19] A. Rahmani et al., “Association between leptin/adiponectin ratio and CAD severity,” BMC Cardiovascular Disorders, vol. 20, p. 474, 2020.
[20] S. Stojanovic et al., “Impact of adiponectin resistance on coronary artery disease severity,” Nigerian Journal of Clinical Practice, vol. 24, no. 8, pp. 1240–1246, 2021.
[21] S. N. Peiu et al., “Ghrelin expression in atherosclerotic plaques,” Journal of Clinical Medicine, vol. 13, no. 13, p. 3737, 2024.
[22] S. Kojima et al., “Variation of plasma adiponectin in myocardial infarction,” Heart, vol. 89, p. 667, 2003.
[23] M. U. Kan et al., “Circulating organokines in coronary artery disease and metabolic syndrome,” Biochemia Medica, vol. 26, no. 4, pp. 679–689, 2025.
[24] N. Katsiki, D. P. Mikhailidis, and C. S. Mantzoros, “Leptin and cardiovascular disease: A narrative review,” Current Opinion in Cardiology, vol. 36, no. 4, pp. 459–467, 2021.
[25] Y. Zhou and L. Rui, “Leptin signaling and leptin resistance,” Frontiers in Endocrinology, vol. 13, p. 823319, 2022.
[26] N. R. Sproston and J. J. Ashworth, “Role of C-reactive protein at sites of inflammation and infection,” Frontiers in Immunology, vol. 12, p. 703074, 2021.
[27] P. M. Ridker, “From C-reactive protein to interleukin-6 to interleukin-1,” Circulation Research, vol. 130, no. 1, pp. 145–156, 2022.
[28] A. Ayala, M. F. Muñoz, and S. Argüelles, “Lipid peroxidation and malondialdehyde,” Oxidative Medicine and Cellular Longevity, vol. 2020, p. 3604381, 2020.
[29] G. Pizzino et al., “Oxidative stress: Harms and benefits,” Oxidative Medicine and Cellular Longevity, vol. 2020, p. 8416763, 2020.
[30] P. Libby, “The changing landscape of atherosclerosis,” Nature, vol. 592, no. 7855, pp. 524–533, 2021.
Copyright (c) 2026 American Journal of Biomedicine and Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
